Sustainability | Lupin Healthcare Limited

Conducted an organisation Green House Gas (GHG) assessment with the support of Carbon Footprint Ltd to understand the GHG emissions associated with current UK operations.

Developed and maintained a carbon reduction plan (CRP) which includes a clear path towards net zero through carbon emission target setting. Our Lupin Healthcare CRP can be found here.

Begun to assess the carbon footprint of supplied products, allowing us to further develop our CRP.

Completed the NHS Evergreen Sustainable Supplier Assessment which supports our understanding and alignment with NHS sustainability priorities, identifying areas for improvement.

Assessed the carbon footprint of our respiratory portfolio and certified all products within this portfolio as carbon neutral

Developed plans to introduce inhalers containing a propellant with 99.9% lower global warming potential than current pMDI technology. Development is expected to complete in 2026 with regulatory filing shortly after. In the meantime, we will continue certify our existing inhaler portfolio as carbon-neutral.

In 2025 Lupin Healthcare acquired Renascience Pharma Ltd and immediately began work to assess the impact of its operations on the environment. Subsequently, a carbon reduction plan was developed and NHS evergreen assessment completed.

Our Renascience CRP can be viewed here.

Based on our current carbon reduction plan we project a 70% reduction in tCO2e emissions per £M turnover by 2030 and a 50% reduction in absolute tCO2e emissions by 2036.

Our CRP can be viewed here.

Set a target and developed a plan to achieve net zero by 2045